IL6 and metabolic syndrome: In joint classification analyses, rising amylin was associated with approximately 2–5 fold higher risk of MetS in the individuals with normal-weight (OR = 2.6 [95% CI: 1.4–4.7] for Q4 vs. OR = 1 [reference group], Figure 2A) and low inflammatory status indicated as in the lowest quartile of CRP (OR = 2.2 [95% CI: 0.7–7.4] for Q4 vs. OR = 1.0 for Q1, Figure 2B), IL-6 (OR = 4.9 [95% CI: 1.6–15.6] for Q4 vs. OR = 1.0 for Q1, Figure 2C), insulin (OR = 2.1 [95% CI: 0.7–6.2] for Q4 vs. OR = 1.0 for Q1, Fig. 2D), and HOMA-IR (OR = 1.9 [95% CI: 0.6–6.0] for Q4 vs. OR = 1.0 for Q1 Fig. 2E).